Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syn-Tech Chem & Pharm CoROCO:1777 +0.41%73 Days Payable is 0.59 as of Dec. 2025, which is 63% below its 10-year median of 1.59. GuruFocus rates ROCO:1777 with a GF Score™ of 73/100 and a GF Value™ of NT$106.95 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 702 Biotechnology companies, Syn-Tech Chem & Pharm Co ranks worse than 99.72% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:1777 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Syn-Tech Chem & Pharm Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syn-Tech Chem & Pharm Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Syn-Tech Chem & Pharm Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Syn-Tech Chem & Pharm Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Syn-Tech Chem & Pharm Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syn-Tech Chem & Pharm Co (ROCO:1777) has a Days Payable of 0.59 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Syn-Tech Chem & Pharm Co and its competitors. This is 63% below median its historical median of 1.59. Over the past decade, Syn-Tech Chem & Pharm Co's Days Payable has ranged from 0.51 to 3.06. According to the industry distribution chart, Syn-Tech Chem & Pharm Co ranks #700 out of 702 companies in the Biotechnology industry, placing it in the top 99.7%.
Is Syn-Tech Chem & Pharm Co's Days Payable too high?
Syn-Tech Chem & Pharm Co's current Days Payable of 0.59 is 63% below median its 10-year median of 1.59. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 3.06. The Biotechnology industry median Days Payable is 113.10. Syn-Tech Chem & Pharm Co's value of 0.59 is 99.5% below this industry median. Based on the distribution chart, Syn-Tech Chem & Pharm Co ranks #700 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Syn-Tech Chem & Pharm Co has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syn-Tech Chem & Pharm Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Syn-Tech Chem & Pharm Co ranks #700 out of 702 companies for Days Payable. This places Syn-Tech Chem & Pharm Co in the lower half of its industry. The industry median Days Payable is 113.10. Syn-Tech Chem & Pharm Co's value of 0.59 is 99.5% below this benchmark. Historically, Syn-Tech Chem & Pharm Co's own Days Payable has ranged from 0.51 to 3.06 over the past decade. While the company's 10-year median is 1.59 vs. the industry median of 113.10, Syn-Tech Chem & Pharm Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syn-Tech Chem & Pharm Co's current Days Payable of 0.59 is 99.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Syn-Tech Chem & Pharm Co and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syn-Tech Chem & Pharm Co's current Days Payable is 0.59, which is 63% below median its own 10-year median of 1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn-Tech Chem & Pharm Co stock overvalued right now?
Based on GuruFocus' analysis, Syn-Tech Chem & Pharm Co (ROCO:1777) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$106.95, compared to a current price of NT$72.80 — trading 31.9% below its estimated fair value. The current Days Payable is 0.59, which is 63% below median its 10-year median of 1.59 and 99.5% below the Biotechnology industry median of 113.10. Syn-Tech Chem & Pharm Co's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Syn-Tech Chem & Pharm Co (ROCO:1777), the current Days Payable is 0.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syn-Tech Chem & Pharm Co (ROCO:1777) Overvalued in 2026?
Based on GuruFocus' analysis, Syn-Tech Chem & Pharm Co stock appears to be undervalued.
The current stock price of NT$72.80 is trading 31.9% below its estimated GF Value™ of NT$106.95.
GuruFocus considers Syn-Tech Chem & Pharm Co to be Significantly Undervalued.
Key valuation signals for ROCO:1777:
Days Payable: 0.59 (63% below median its 10-year median of 1.59)
GF Value™: NT$106.95 vs. price of NT$72.80 (31.9% below fair value)
Industry Position: 99.5% below the Biotechnology median (#700 of 702)
No single metric tells the full story. See the ROCO:1777 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syn-Tech Chem & Pharm Co Ltd is engaged in the manufacture and sale of western medicines, veterinary drugs, food additives, cosmetics, and related businesses. It manufactures and sells Active Pharmaceutical Ingredients for domestic and foreign pharmaceutical companies and trade agents. Its products include Alfuzosin HCl, Atomoxetine HCl, Chlorzoxazone, Chlormezanone, Cloperastine HCl, Crotamiton, Diclofenac Epolamine, and others. It generates the majority of its revenue from Asia excluding Taiwan.
73GF Score
Get the complete analysis for ROCO:1777
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1777 has been successfully added to your 
